cyclophosphamide,fludarabine,lisocabtagene maraleucel
bms
['transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'transcend fl', 'lymsm', 'liso-cel']
transcend fl liso-cel in r/r fl #17icml
- safety in 2l, efficacy in 3l (???)
- orr 97% (cr 94%), mdor nr for mfu 16 mos
- 1-yr pfs 81%
- high grade crs 1%, icans 2%, 13 deaths (1 hlh death)
#lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈